Angelika Eggert

Charité - Universitätsmedizin Berlin — Germany

Medicine · Health Sciences

72h-index18.3kcitations760works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(400), Cancer, Hypoxia, and Metabolism(82), Cancer therapeutics and mechanisms(68), Protein Degradation and Inhibitors(63), Childhood Cancer Survivors' Quality of Life(54)

Publications759 total

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology
npj Precision Oncology·2026Open Access
Developing evidence‐based, cost‐effective <scp>P4</scp> cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology·2025Open Access
Fractal Dimension of High-Risk Neuroblastoma Vascularity in MRI Is Associated with Chemotherapy Response and Event-Free Survival
Radiology Imaging Cancer·2025Open Access
Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors
Nature Communications·2025Open Access
Identification of full-length circular RNAs linked with therapy resistance of pediatric cancers
2025Open Access
Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model
Frontiers in Immunology·2025Open Access
Number of affected lymph nodes predicts outcome in extremity rhabdomyosarcoma
European Journal of Surgical Oncology·2025Open Access
Harmonization of Reporting of ALK Genetic Alterations in Neuroblastoma
Journal of Molecular Diagnostics·2025Open Access
Table S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S4 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S5 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S6 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Data from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S8 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S1 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Figure S7 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Table S3 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
Table S2 from Extrachromosomal DNA–Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in &lt;i&gt;MYCN&lt;/i&gt;-Amplified Cancers
2025Open Access
page 1 of 38Next →

Frequent Co-authors

Johannes H. Schulte(26), Alexander Schramm(26), Frank Speleman(14), Jo Vandesompele(13), Frank Westermann(11), Matthias Fischer(11), Katleen De Preter(11), Lukas C. Heukamp(9), Theresa Thor(8), Kristian W. Pajtler(7), Pieter Mestdagh(7), Garrett M. Brodeur(7), Barbara Hero(6), Rogier Versteeg(6), Ludger Klein‐Hitpaß(6), Anton G. Henssen(6), Kathy Astrahantseff(6), Naohiko Ikegaki(6), Michael A. Grotzer(6), Arndt Borkhardt(5)